Login
$JNJ
$282.90 +$0.35 (0.12%) After hours

$JNJ 8-K SEC Filings

Filed On Filing
13 Oct 2026 8-K: Results of Operations and Financial Condition

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

04 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

29 Jul 2026 8-K: Regulation FD Disclosure

Investor contact:Jessica [email protected]

28 Jul 2026 8-K: Regulation FD Disclosure

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

15 Jul 2026 8-K: Results of Operations and Financial Condition

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

28 Apr 2026 8-K: Submission of Matters to a Vote of Security Holders

(a) The 2026 Annual Meeting of Shareholders of the Company was held on April 23, 2026.

14 Apr 2026 8-K: Results of Operations and Financial Condition; Other Events

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

21 Jan 2026 8-K: Results of Operations and Financial Condition

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

14 Oct 2025 8-K: Results of Operations and Financial Condition; Other Events

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

09 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

16 Jul 2025 8-K: Results of Operations and Financial Condition

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

10 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

30 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23rd that he will join Goldman Sachs as a Partner. The retirement will be effective May 31, 2025...

15 Apr 2025 8-K: Results of Operations and Financial Condition; Other Events

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

03 Apr 2025 8-K: Regulation FD Disclosure

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

26 Feb 2025 8-K: Other Events

Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC (the “Managers”) understand that Johnson & Johnson, a New Jersey corporation (the “Company”), proposes to issue and sell €600,000,000 aggregate...

20 Feb 2025 8-K: Other Events

Citigroup Global Markets Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC (the “Managers”) understand that Johnson & Johnson, a New Jersey corporation (the “Company”), proposes to issue and sell $750,000,000 aggregate principal...

22 Jan 2025 8-K: Results of Operations and Financial Condition

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

15 Oct 2024 8-K: Results of Operations and Financial Condition

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

20 Sep 2024 8-K: Regulation FD Disclosure

Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support